US FDA Nears Regulatory Decision on Junshi Biosciences’ PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is approaching a significant regulatory milestone...
Acorda Therapeutics Strikes Deal with Hangzhou Chance for Inbrija Distribution in China
US-based Acorda Therapeutics Inc., (Nasdaq: ACOR) has announced a distribution and supply agreement with Hangzhou...
RemeGen Ltd Receives Approval for Phase I Clinical Study of RC198 in Solid Tumors
RemeGen Ltd (HKG: 9995) has announced that it has received approval from the Human Research...
Grand Pharmaceutical Group Completes Enrollment in Phase III Study for Ryaltris Nasal Spray
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the completion of all subject enrollment...
Alphamab Oncology and CSPC Pharma Get Green Light for KN026 Phase III Study in Breast Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced receiving...
Eyenovia, Inc. Receives FDA Approval for Mydcombi, a First-of-Its-Kind Ophthalmic Spray
US-based Eyenovia, Inc. (NASDAQ: EYEN) has announced obtaining market approval from the US Food and...
NMPA Releases 67th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 67th batch of reference drugs for...
Jiangsu Hengrui Pharmaceuticals Advances SHR-1819, SHR-2002, and Adebrelimab into New Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals for its...
Ascletis Pharma Receives Approval for Phase IIa Study of ASC10 for RSV Infection
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the green light to conduct a...
EQRx Inc. Abandons Plans for Low-Cost Drugs, Terminates Development of Three China-Sourced Products
US-based biotech EQRx Inc., (Nasdaq: EQRX) has disclosed in its Q4 2022 financial report a...
Shunxi Holding Group Secures Licensing Deal for Cartherics’ CTH-004 in Greater China
China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm...
AstraZeneca’s MEK Inhibitor Koselugo Approved in China for Pediatric NF1-Related PN
UK major AstraZeneca (AZ, NASDAQ: AZN) has announced that its mitogen-activated protein kinase (MEK) inhibitor,...
Shenzhen’s Angio8 Secures Tens of Millions in Series A Financing for Surgical Robot Development
Angio8, a Shenzhen-based developer of vascular interventional surgical robots, has reportedly raised tens of millions...
BeiGene’s Brukinsa Receives NMPA Approval for Expanded Use in Leukemia and Lymphoma
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it has received approval...
Shanghai Junshi Biosciences’ Tuoyi Shows Promise in Phase III Study for ES-SCLC
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced encouraging results from the...
Tianjin, Shandong, and Hainan Provinces Announce VBP Backup Suppliers for Round 8
Tianjin, Shandong, and Hainan provinces in China have released their lists of backup suppliers following...
Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment
China-based Suzhou GenAssist Therapeutic Co., Ltd has announced that the US Food and Drug Administration...
Sinopharm Partners with Fudan University to Establish National Innovation Platform
China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Fudan...
Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...
Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline
China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100...